The Journal of Allergy and Clinical Immunology: In Practice
Correspondence and RepliesIntranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children
Section snippets
Acknowledgments
We are grateful to the children who participated in this study.
References (4)
- et al.
Safe vaccination of egg allergic patients with live attenuated influenza vaccine
J Allergy Clin Immunol Pract
(2015) - et al.
Ovalbumin content of 2010-2011 influenza vaccines
J Allergy Clin Immunol
(2011)
Cited by (5)
Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System
2017, VaccineCitation Excerpt :It is possible that egg proteins in inactivated influenza vaccines play little or no role, and that hypersensitivity reflects a complex interaction of current and past environmental exposures in an immunologically vulnerable milieu. Severe allergic reactions to egg-based influenza vaccines in persons with egg allergy are uncommon [13–17]. In a randomized, prospective, double-blind, placebo controlled trial, Greenhawt et al. [18] evaluated the safety of TIV in children with a history of severe egg allergy, including anaphylaxis.
Review: The Nose as a Route for Therapy. Part 2 Immunotherapy
2021, Frontiers in AllergyDiagnosis and management of hypersensitivity reactions to vaccines
2020, Expert Review of Clinical Immunology
This report is independent research commissioned and funded by the Department of Health Policy Research Programme (National Vaccine Evaluation Consortium, 039/0031). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health.
P. J. Turner is in receipt of a Clinician Scientist award funded by the UK Medical Research Council (Grant reference MR/K010468/1) and has received research support from the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre awards to Imperial College London Healthcare NHS Trust.
Conflicts of interest: P. J. Turner has received research support from the Department of Health, NHS National Institute for Health Research, and UK Medical Research Council. M. Erlewyn-Lajeunesse has received support for attendance at scientific meetings from Allergy Therapeutics, ALK Albelo, MEDA Pharmaceuticals, and Thermo Fisher.